Advanced Medical Optics Inc (1168335) SEC Filing 10-Q Quarterly report for the period ending Friday, September 28, 2007

Abbott Medical Optics Inc

CIK: 1168335





Investors:    Media:
Sheree Aronson, Corporate Vice President,    Steve Chesterman, Manager, Corporate
Investor Relations and Corporate Communications    Communications
(714) 247-8290    (714) 247-8711
Mark Levin, Manager, Investor Relations   
(714) 247-8465   



Pro Forma Laser Vision Correction Sales Rise 15.8% on Global Procedure Growth and Unit Placements

Cataract/Implant Sales Grow 5.2% on Strong IOL and Phacoemulsification Performance

Eye Care Business Rebounds Following May 2007 Recall; Global Re-Launch of Branded Multipurpose Solution Underway

Company Reaffirms 2007 and 2008 Financial Guidance

(SANTA ANA, CA), October 25, 2007 – Advanced Medical Optics, Inc. (AMO) [NYSE: EYE], a global leader in ophthalmic surgical devices and eye care products, today announced financial results for the third quarter of 2007.

The company’s third-quarter 2007 net sales rose 5.6 percent to $273.2 million. The sales increases related to the IntraLase Corp. and WaveFront Sciences, Inc. acquisitions and organic growth were partially offset by lost sales related to the May 2007 contact lens care solutions recall. Foreign currency impacts increased net sales by 2.1 percent.

AMO reported a third-quarter net loss under Generally Accepted Accounting Principles (GAAP) of $25.9 million, or a loss of $0.43 per share, which included the impact of the recall. These results also included the following items, which combined to increase the net loss per share by approximately $0.08:



$5.3 million in pre-tax charges related to integration of acquisitions.



$2.4 million pre-tax loss on derivative instruments.



Estimated tax effects related to the items mentioned above, totaling $3.1 million.

In the same period last year, AMO reported GAAP net income of $87.2 million, or $1.42 per diluted share. A net total of $97.3 million in pre-tax items increased third-quarter 2006 results by $0.92 per share. These items included a pre-tax net gain of $102.9 million related to the

The following information was filed by Abbott Medical Optics Inc on Thursday, October 25, 2007 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Abbott Medical Optics Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Abbott Medical Optics Inc.


Assess how Abbott Medical Optics Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Abbott Medical Optics Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2007 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
CIK: 1168335
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-07-238366
Submitted to the SEC: Wed Nov 07 2007 3:31:49 PM EST
Accepted by the SEC: Wed Nov 07 2007
Period: Friday, September 28, 2007
Industry: Surgical And Medical Instruments And Apparatus

External Resources:

Bookmark the Permalink: